E09.3533 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral

Name of the Condition

• Drug or Chemical Induced Diabetes Mellitus with Proliferative Diabetic Retinopathy with Traction Retinal Detachment Not Involving the Macula, Bilateral (ICD-10 Code: E09.3533)

Summary

Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral is a condition where elevated blood sugar levels, caused by exposure to specific medications or chemicals, lead to advanced eye complications. This form of diabetes is directly attributable to external factors that disrupt glucose metabolism, resulting in hyperglycemia and associated retinal damage. Proliferative diabetic retinopathy is characterized by abnormal blood vessel growth in the retina, and traction retinal detachment not involving the macula occurs when scar tissue pulls the retina away from its normal position, potentially threatening peripheral vision in both eyes.

Causes

The condition is caused by exposure to drugs or chemicals that impair glucose regulation, leading to uncontrolled hyperglycemia. Common culprits include medications (e.g., glucocorticoids, antipsychotics, or diuretics) and toxins that reduce insulin secretion or increase insulin resistance. These substances trigger hyperglycemia, which, if untreated, progresses to proliferative diabetic retinopathy and traction retinal detachment due to damage to blood vessels in the retina.

Risk Factors

Risk factors include prolonged use of hyperglycemic-inducing medications, pre-existing insulin resistance, genetic predisposition to diabetes, and exposure to certain chemicals. Individuals with a history of diabetes or those taking medications known to affect glucose metabolism are at higher risk.

Symptoms

Symptoms may include blurred vision, floaters, peripheral vision loss, or visual distortions. Some individuals may experience no symptoms until significant retinal damage has occurred. Bilateral involvement may present with symmetric visual changes in both eyes.

Diagnosis

Diagnosis involves a comprehensive eye exam, including dilated retinal evaluation, optical coherence tomography (OCT), and fluorescein angiography to assess retinal blood vessels. Blood tests to confirm hyperglycemia and identify the causative drug or chemical are also performed.

Treatment Options

Treatment focuses on managing blood sugar levels, discontinuing the offending agent (if possible), and addressing retinal complications. Laser photocoagulation, intravitreal injections, or surgery may be used to treat proliferative retinopathy and retinal detachment. Regular monitoring is essential to prevent progression.

Prognosis and Follow-Up

Prognosis depends on early intervention and control of blood sugar. With proper management, vision loss may be minimized, but advanced cases can lead to permanent peripheral vision impairment. Follow-up includes regular eye exams and glycemic monitoring to track disease progression.

Complications

Complications include permanent vision loss, macular edema (if the macula becomes involved), and increased risk of other diabetic eye conditions. Bilateral involvement may significantly impact daily functioning and quality of life.

Lifestyle & Prevention

Lifestyle modifications include avoiding known hyperglycemic agents, maintaining a balanced diet, and regular exercise to support glucose control. Preventive measures involve careful medication management and routine eye screenings for those at risk.

When to Seek Professional Help

Seek immediate medical attention for sudden vision changes, increased floaters, or persistent visual disturbances. Early evaluation is critical to prevent irreversible retinal damage.

Tips for Medical Coders

Document the bilateral nature of the traction retinal detachment and confirm the causative drug or chemical exposure. Ensure the diagnosis aligns with the clinical findings and specify the absence of macular involvement. Accurate coding requires clear documentation of the retinal detachment's location and laterality.